
Post-trial analyses found average weight loss of 25% at 68 weeks, while Novo said further work is needed to confirm the findings.
Novo Nordisk said post-trial analyses found that women taking its experimental obesity drug CagriSema lost an average of 25% of their weight at 68 weeks. The comparison group taking placebo lost 3%.
The analysis covered roughly 2,300 women with obesity or overweight. The results assume all patients stayed on treatment without interruptions, and Novo said further work is needed to confirm the analyses’ hypotheses.
A separate analysis of about 1,900 women found average weight loss of 26.7% among premenopausal women, 24.8% among perimenopausal women and 23.1% among postmenopausal women. Novo said CagriSema was also linked to reduced abdominal fat across the groups.
CagriSema combines semaglutide and cagrilintide. The drug is expected to launch early next year.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.